US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Fintel reports that on November 26, 2024, Morgan Stanley downgraded their outlook for Alector (NasdaqGS:ALEC) from ...

Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

BTIG analyst Thomas Shrader maintained a Buy rating on Alector (ALEC – Research Report) yesterday and set a price target of $5.00. Don't Miss our Black Friday Offers: Unlock your investing potential ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.